Join John McCamant LIVE at The MoneyShow San Francisco!

Join John McCamant LIVE at The MoneyShow San Francisco!

Myovant: Emerging Leader in Woman's Health

11/10/2017 5:00 am EST


John McCamant

Editor, Medical Technology Stock Letter

Myovant (MYOV) is an emerging biotech leader focused on developing and commercializing innovative therapies for women’s health and endocrine diseases, notes John McCamant, biotech sector expert and editor of The Medical Technology Stock Letter.

Its lead drug development candidate, Relugolix, is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that rapidly lowers estrogen and progesterone in women and testosterone levels in men when administered once-daily.

In our view, the drug candidate has the potential to a best in class molecule with superior efficacy, an improved safety profile and more convenient oral dosing options.

Get Top Pros' Top Picks, MoneyShow’s free investing newsletter »

The compound is currently being tested in three Phase III trials, two in woman’s health and one in prostate cancer.

One of the company’s key strengths is its experienced leadership team, highlighted by the demonstrated success of its CEO, Dr. Lynn Seely. Dr. Seely was Chief Medical Officer at Medivation (MDVN) from 2005-2015 and led the development of XTANDI.

Adding to her stellar resume, she is board-certified in internal medicine and endocrinology and metabolism, and completed a clinical fellowship in endocrinology and metabolism at UC San Diego.

In addition to Dr. Seely, the team includes Bryan Selby who spent nearly a decade at Medivation, most recently as SVP, Product Strategy, and Dr. Laura Williams, M.D., MPH who spent 18 years at Abbott (ABT) and AbbVie (ABBV) and served as R&D Group Project Leader in Women’s Health.

In our view, the company has an excellent combination of an attractive Phase III asset and an experienced management team assembled to maximize shareholder value through astute drug development. We are initiating coverage of Myovant as a buy.

Subscribe to John McCamant's The Medical Technology Stock Letter here…

Related Articles on HEALTHCARE

Keyword Image
Alkermes: Bad News Biotech Buy?
05/16/2019 5:00 am EST

Alkermes plc (ALKS) recently released its Q1:19 financial results that showed a big miss for Aristad...